Atlas Trials

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

Clinical trial NCT06357975 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06357975
Sponsor
National Cancer Institute (NCI)
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory LymphomaRefractory Malignant Solid NeoplasmRefractory Multiple Myeloma
Start date
2016-07-29
Primary completion
2022-11-15
Enrollment
44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.